Erasca/$ERAS
1D1W1MYTD1Y5YMAX
Capital at risk
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
- Ticker
- $ERAS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 103
- Headquarters
- San Diego, United States
- Website
- www.erasca.com
Erasca Metrics
BasicAdvanced
$5.4B
-
-$0.97
0.65
-
Price and volume
Market cap
$5.4B
Beta
0.65
52-week high
$24.28
52-week low
$1.65
Average daily volume
3.7M
Financial strength
Current ratio
8.294
Quick ratio
8.08
Long term debt to equity
0.109
Total debt to equity
0.124
Profitability
EBITDA (TTM)
-147.743
Management effectiveness
Return on assets (TTM)
-21.39%
Return on equity (TTM)
-78.25%
Valuation
Price to book
13.27
Price to tangible book (TTM)
13.27
Price to free cash flow (TTM)
-18.024
Free cash flow yield (TTM)
-5.55%
Free cash flow per share (TTM)
-0.852
Growth
Earnings per share change (TTM)
114.40%
3-year earnings per share growth (CAGR)
-17.36%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Analyst projections of the future price of Erasca stock.
Bulls say / Bears say
ERAS-0015 produced a 57% eight-week overall response rate in seven patients with second-line-or-later KRAS G12X pancreatic cancer at the recommended dose. All responding patients remained on treatment at the data cut-off, with no dose-limiting toxicities or treatment-related discontinuations reported. (GlobeNewswire)
The FDA granted Fast Track designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. This gives Erasca more structured interaction with regulators as it prepares a planned Phase 3 pancreatic trial and further lung-cancer studies. (BioSpace)
Erasca strengthened its funding position with a July offering that generated about $632.5 million gross, while management said the post-offering cash position should fund its key milestones. That reduces near-term financing pressure as the company advances ERAS-0015 and prepares ERAS-4001 data. (BioSpace, BioSpace)
The headline 57% eight-week response rate is preliminary, includes unconfirmed responses and came from only seven patients at the recommended dose. The trial is still Phase 1, so durability and performance in larger, controlled studies remain unproven. (GlobeNewswire, BioSpace)
Erasca stopped developing naporafenib and terminated its Novartis licence, leaving the investment case more concentrated in ERAS-0015, ERAS-4001 and the early ERAS-12 programme. That narrows diversification and makes a setback in the lead RAS programmes more damaging. (StockTitan)
The July offering raised $632.5 million gross by selling 36.1 million new shares, diluting existing holders. Erasca has no product revenue and says it may need further equity, debt or other funding before any product can generate meaningful sales. (BioSpace, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Upcoming events
No upcoming events
Erasca News
AllArticlesVideos
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp3 weeks ago
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp4 weeks ago
ERASCA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action - ERAS
Newsfile Corp1 month ago
Funds containing Erasca
AllUSDGBPEUR
Fund name | Fund size | $ERAS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.34% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.34% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.12% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.